Clinical Report: FDA Clears Nocturnal IOP Device
Overview
Balance Ophthalmics has received FDA 510(k) clearance for a wireless-enabled device designed to lower intraocular pressure (IOP) during sleep in adults with open-angle glaucoma. The FSYX Ocular Pressure Adjusting Pump (OPAP) demonstrates a 39% mean reduction in nighttime eye pressure across clinical studies.
Background
Intraocular pressure (IOP) management is crucial in glaucoma care, particularly as IOP often peaks during sleep when conventional therapies may be less effective. The introduction of devices like the FSYX OPAP, which includes wireless communication for real-time monitoring, addresses the need for targeted nocturnal IOP reduction, potentially improving patient outcomes.
Data Highlights
The FSYX OPAP has been evaluated in 12 clinical studies involving over 600 eyes, showing:
- 39% mean reduction in nighttime eye pressure.
- No device-related serious adverse events reported, indicating a favorable safety profile.
Key Findings
- The FSYX OPAP is the first device specifically designed for nocturnal IOP reduction.
- Wireless communication allows for real-time monitoring of patient adherence and usage data.
- It is intended to be used alongside existing glaucoma treatments.
- The device is expected to be available to eye care practices in Q4 2026, pending final regulatory processes.
- Clinical evaluations support its efficacy in reducing nighttime IOP.
Clinical Implications
The FSYX OPAP offers a novel approach to managing nocturnal IOP, which is critical for preventing glaucoma progression. Eye care practitioners should consider integrating this device into treatment plans for patients with open-angle glaucoma, particularly those who experience elevated IOP during sleep, while continuing existing therapies.
Conclusion
The FDA clearance of the FSYX OPAP marks a significant advancement in glaucoma management, providing a targeted solution for nocturnal IOP reduction. This device may enhance patient care by offering new insights into IOP behavior during sleep, particularly through its wireless monitoring capabilities.
Related Resources & Content
- Balance Ophthalmics, Balance Ophthalmics, 2023 -- FDA Clears Nocturnal IOP Device
- Glaucoma Physician, FDA Clears IOP Measuring Device, 2018 -- FDA Clears IOP Measuring Device
- Ophthalmology Management, FDA Grants DeNovo Classification for Treatment to Lower IOP Recommendations, 2024 -- FDA Grants DeNovo Classification for Treatment to Lower IOP
- Ophthalmology Management — FDA Clears Wireless Pressure Goggles for Glaucoma
- Primary Open-Angle Glaucoma Preferred Practice Pattern® - PubMed
- Circadian rhythm of intraocular pressure | The Journal of Physiological Sciences | Springer Nature Link
- Device Classification Under Section 513(f)(2)(De Novo)
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
